person · Reporting owner
Markelewicz Robert J. Jr.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Abpro Holdings, Inc.ABP · Entity 8582 | Chief Medical Officer | November 13, 2024 | November 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Abpro Holdings, Inc.
Report date November 13, 2024 · Filed November 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2038-12-19 | Direct | 24,300 |
Reported balance
After 2024-11-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-13 · Grant · Acquired 24,300 · Balance 24,300 F1: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2: This stock option award is 100% vested. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2028-09-28 | Direct | 538,600 |
Reported balance
After 2024-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-13 · Grant · Acquired 538,600 · Balance 538,600 F1: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2: This stock option award is 100% vested. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2031-04-19 | Direct | 29,800 |
Reported balance
After 2024-11-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-13 · Grant · Acquired 29,800 · Balance 29,800 F1: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2: This stock option award is 100% vested. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2030-06-19 | Direct | 40,800 |
Reported balance
After 2024-11-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-11-13 · Grant · Acquired 40,800 · Balance 40,800 F1: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2: This stock option award is 100% vested. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2031-04-19 | Direct | 41,700 |
Reported balance
After 2024-11-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-11-13 · Grant · Acquired 41,700 · Balance 41,700 F1: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F3: This stock option award was initially granted by Abpro to the reporting person on April 14, 2021. The sock option award vests as follows: twenty-five percent (25%) the shares subject to the option vested on April 14, 2022, and the remaining seventy-five percent (75%) of the total number of shares subject to the option vest in thirty-six (36) substantially equal monthly installments thereafter, subject to the reporting person's continuous service to the Issuer through such date. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2028-12-19 | Direct | 74,600 |
Reported balance
After 2024-11-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-11-13 · Grant · Acquired 74,600 · Balance 74,600 F1: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2: This stock option award is 100% vested. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2032-02-18 | Direct | 10,200 |
Reported balance
After 2024-11-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-11-13 · Grant · Acquired 10,200 · Balance 10,200 F1: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F4: This stock option award was initially granted by Abpro to the reporting person on February 18, 2022. The sock option award vests as follows: twenty-five percent (25%) the shares subject to the option vested on February 18, 2023, and the remaining seventy-five percent (75%) of the total number of shares subject to the option vest in thirty-six (36) substantially equal monthly installments thereafter, subject to the reporting person's continuous service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro.
F2: This stock option award is 100% vested.
F3: This stock option award was initially granted by Abpro to the reporting person on April 14, 2021. The sock option award vests as follows: twenty-five percent (25%) the shares subject to the option vested on April 14, 2022, and the remaining seventy-five percent (75%) of the total number of shares subject to the option vest in thirty-six (36) substantially equal monthly installments thereafter, subject to the reporting person's continuous service to the Issuer through such date.
F4: This stock option award was initially granted by Abpro to the reporting person on February 18, 2022. The sock option award vests as follows: twenty-five percent (25%) the shares subject to the option vested on February 18, 2023, and the remaining seventy-five percent (75%) of the total number of shares subject to the option vest in thirty-six (36) substantially equal monthly installments thereafter, subject to the reporting person's continuous service to the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2024 Filed Nov 15, 2024 21:29 UTC | Abpro Holdings, Inc. ABP · Entity 8582 | GrantStock option (right to buy) · Derivative | 10,200 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001474506-24-000246 · primary_doc.xml · derivative · entry 7 Markelewicz Robert J. Jr. · CIK 0002044590 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,200 Underlying: Common Stock, par value $0.0001 per share · 10,200 shares Expires 2032-02-18 F1 · shares: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F4 · derivative.exercise_date: This stock option award was initially granted by Abpro to the reporting person on February 18, 2022. The sock option award vests as follows: twenty-five percent (25%) the shares subject to the option vested on February 18, 2023, and the remaining seventy-five percent (75%) of the total number of shares subject to the option vest in thirty-six (36) substantially equal monthly installments thereafter, subject to the reporting person's continuous service to the Issuer through such date. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:29 UTC | Abpro Holdings, Inc. ABP · Entity 8582 | GrantStock option (right to buy) · Derivative | 74,600 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001474506-24-000246 · primary_doc.xml · derivative · entry 6 Markelewicz Robert J. Jr. · CIK 0002044590 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,600 Underlying: Common Stock, par value $0.0001 per share · 74,600 shares Expires 2028-12-19 F1 · shares: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2 · derivative.exercise_date: This stock option award is 100% vested. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:29 UTC | Abpro Holdings, Inc. ABP · Entity 8582 | GrantStock option (right to buy) · Derivative | 41,700 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001474506-24-000246 · primary_doc.xml · derivative · entry 5 Markelewicz Robert J. Jr. · CIK 0002044590 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,700 Underlying: Common Stock, par value $0.0001 per share · 41,700 shares Expires 2031-04-19 F1 · shares: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F3 · derivative.exercise_date: This stock option award was initially granted by Abpro to the reporting person on April 14, 2021. The sock option award vests as follows: twenty-five percent (25%) the shares subject to the option vested on April 14, 2022, and the remaining seventy-five percent (75%) of the total number of shares subject to the option vest in thirty-six (36) substantially equal monthly installments thereafter, subject to the reporting person's continuous service to the Issuer through such date. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:29 UTC | Abpro Holdings, Inc. ABP · Entity 8582 | GrantStock option (right to buy) · Derivative | 40,800 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001474506-24-000246 · primary_doc.xml · derivative · entry 4 Markelewicz Robert J. Jr. · CIK 0002044590 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,800 Underlying: Common Stock, par value $0.0001 per share · 40,800 shares Expires 2030-06-19 F1 · shares: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2 · derivative.exercise_date: This stock option award is 100% vested. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:29 UTC | Abpro Holdings, Inc. ABP · Entity 8582 | GrantStock option (right to buy) · Derivative | 29,800 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001474506-24-000246 · primary_doc.xml · derivative · entry 3 Markelewicz Robert J. Jr. · CIK 0002044590 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,800 Underlying: Common Stock, par value $0.0001 per share · 29,800 shares Expires 2031-04-19 F1 · shares: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2 · derivative.exercise_date: This stock option award is 100% vested. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:29 UTC | Abpro Holdings, Inc. ABP · Entity 8582 | GrantStock option (right to buy) · Derivative | 538,600 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001474506-24-000246 · primary_doc.xml · derivative · entry 2 Markelewicz Robert J. Jr. · CIK 0002044590 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,600 Underlying: Common Stock, par value $0.0001 per share · 538,600 shares Expires 2028-09-28 F1 · shares: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2 · derivative.exercise_date: This stock option award is 100% vested. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:29 UTC | Abpro Holdings, Inc. ABP · Entity 8582 | GrantStock option (right to buy) · Derivative | 24,300 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001474506-24-000246 · primary_doc.xml · derivative · entry 1 Markelewicz Robert J. Jr. · CIK 0002044590 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,300 Underlying: Common Stock, par value $0.0001 per share · 24,300 shares Expires 2038-12-19 F1 · shares: Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") of rollover stock options awards in connection with the closing of the business combination between Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro. F2 · derivative.exercise_date: This stock option award is 100% vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.